Unlabelled: Fatal hepatotoxicity associated with ciprofloxacin is extremely rare. This is the second fully investigated case of fulminant hepatotoxicity due to ciprofloxacin in a male patient previously ciprofloxacin tolerant. The patient's medical history included stable Waldenstrom's macroglobulinaemia, inguinal hernia repair, prostate cancer (radiotherapy in 2006) and idiopathic Parkinson's disease. Extensive investigation for progressive liver failure confirmed drug-induced liver injury.
Learning Points: Idiosyncratic drug-induced liver injury is rare, so a history of consumption of any potentially offending drug is vital.Exhaustive searches for alternative causes are imperative and a comprehensive history is essential, including a travel history with microbiological investigations if necessary; potential drug-induced liver injury must always be considered.The patient's age and past medical history may affect outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473698 | PMC |
| http://dx.doi.org/10.12890/2020_001612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of drug-drug interaction between rosuvastatin and tacrolimus and the risk of hepatic injury in rats.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Minde Road No. 1, Nanchang, 330006, Jiangxi, China.
Multimorbidity, therapeutic complexity, and polypharmacy, which greatly increases the risk of drug-drug interactions (DDIs) and adverse medical outcomes, have become important and growing challenges in clinical practice. Statins are frequently prescribed to manage post-transplant dyslipidemia and reduce overall cardiovascular risk in solid organ transplant recipients. This study aimed to determine whether rosuvastatin has significant DDIs with tacrolimus (the first-line immunosuppressant) and to evaluate the risk of hepatotoxicity associated with concomitant therapy.
View Article and Find Full Text PDFDirect-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis.
Biomedicines
December 2024
Master Program in Clinical Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Glecaprevir/pibrentasvir (G/P) and elbasvir/grazoprevir (EBR/GZR) are effective treatments for chronic hepatitis C (CHC), especially in patients with chronic kidney disease (CKD). However, both regimens carry a risk of drug-induced liver injury (DILI). This study investigates the association between renal failure and DILI, using real-world data, and assesses the effectiveness of these treatments in peritoneal dialysis patients.
View Article and Find Full Text PDFStudying the intracellular bile acid concentration and toxicity in drug-induced cholestasis: Comprehensive LC-MS/MS analysis with human liver slices.
Toxicol In Vitro
January 2025
University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands. Electronic address:
Drug-induced cholestasis (DIC) is a leading cause of drug-induced liver injury post-drug marketing, characterized by bile flow obstruction and toxic bile constituent accumulation within hepatocytes. This study investigates the toxicity associated with intracellular bile acid (BA) accumulation during DIC development. Using liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis, we examined intracellular BA concentrations in human precision-cut liver slices (PCLS) following the administration of cyclosporin A and chlorpromazine, both with and without an established BA mixture.
View Article and Find Full Text PDFSW033291 promotes liver regeneration after acetaminophen-induced liver injury in mice.
Biochem Biophys Res Commun
January 2025
College of Pharmacy, Xinjiang Medical University, Urumqi, 830054, Xinjiang, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang, China. Electronic address:
Acetaminophen (APAP) is a commonly utilized antipyretic and analgesic drug. Overdose of APAP is a primary contributor to drug-induced liver injury and acute liver failure (ALF). SW033291 has been shown to play a role in tissue regeneration in various diseases; however, its potential to facilitate liver regeneration following APAP-induced hepatic injury remains unexamined.
View Article and Find Full Text PDFDrug-Induced Liver Injury Associated With Emerging Cancer Therapies.
Liver Int
February 2025
Department of Clinical Pharmacology and Toxicology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Targeted therapies and immunotherapies have shown great promise as best-in-class treatments for several cancers with respect to efficacy and safety. While liver test abnormalities are rather common in patients treated with kinase inhibitors or immunotherapy, events of severe hepatotoxicity in these patients are rare in comparison with those associated with chemotherapeutics. The underlying mechanisms and risk factors for severe hepatotoxicity with novel oncology therapies are not well understood, complicating the drug-induced liver injury (DILI) risk assessment in the preclinical and clinical phases of drug development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!